Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Background A treat-to-target therapeutic approach is emerging as the new standard of care
for treating inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis …

Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-
TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring …

Introduction: The association between infliximab (IFX) and fecal calprotectin (FC) levels on
one hand, and the clinical and endoscopic response of patients with inflammatory bowel …

Inflammatory bowel disease (IBD) treatment targets have progressed over time from clinical
response to clinical and endoscopic remission. Several data have shown a positive …

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that is characterized by
transmural inflammation that can affect any part of the gastrointestinal tract, leading to …

Introduction Therapeutic drug monitoring (TDM) is useful for optimizing monoclonal
antibodies (mAbs) for the treatment of immune-mediated inflammatory disorders including …